Article | July 5, 2023

RWD/RWE In 2023: Regulatory Policy World Tour

Source: DIA

By Elena Popa, Max Wegner, Patrick Brady, Vada Perkins, Shefali Goyal, and Ulrike Bodesheim, Bayer AG

GettyImages-1356381571 world data

The rapid progress and deployment of COVID-19 vaccines owe their success to the invaluable contributions of real-world data and evidence (RWD/RWE). However, the pursuit of utilizing, comprehending, and embracing RWD/RWE in the pharmaceutical development process has long been ongoing.

While regulatory bodies like the U.S. FDA, EMA, and Taiwan FDA (TFDA) have adopted a more practical approach in formulating guidelines, regulations, and frameworks in recent years, it is crucial that the life sciences industry establish harmonized international collaboration and regulatory standards that adhere to similar scientific principles, if not identical ones.

With that goal in mind, there is still much work to be done in terms of enhancing predictability, collecting and interpreting data, refining methodologies, and obtaining acceptance from regulators, HTAs, and payers. In 2023, many anticipate the ICH Assembly’s take on the Reflection Paper drafted by FDA, EMA, and Health Canada, focusing on “international harmonization of real-world evidence terminology, and convergence of general principles regarding planning and reporting of studies using real-world data, with a focus on effectiveness of medicines.”

Learn more about what the industry considers to be priorities for the year, as well as RWD/RWE focuses within each region around the globe.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader